Pfizer says CDC’s ACIP issued ‘favorable vote’ for Abrysvo for RSV

Pfizer says it has “broadened its portfolio” of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, or ACIP, following a favorable vote for Abrysvo, the company’s bivalent RSV prefusion F vaccine, as a maternal immunization. “This is the first-ever fall in which eligible individuals can receive Pfizer vaccines to help protect against RSV, COVID-19, and pneumococcal pneumonia,” the company stated. “Today, ACIP recommended maternal RSV vaccine for pregnant people during 32 through 36 weeks gestation, using seasonal administration, to prevent RSV lower respiratory tract infection in infants. This provisional recommendation will be official once it is reviewed and adopted by the director of the CDC,” the company noted.